ASX: RMD

ResMed result a breath of fresh air

Wilson Asset Management

On Wednesday, sleep apnoea treatment manufacturer ResMed (ASX: RMD) revealed strong second quarter results including a 17% increase in revenue compared to the same period of the prior year. In announcing the results, ResMed chief executive Mick Farrell said the company was well positioned to adapt to the Trump administration’s... Show More

reporting season ASX: RMD